Last reviewed 2026-04-23 · How we verify

Paliperidone ER OROS

Paliperidone ER OROS is an atypical antipsychotic that works by blocking dopamine receptors in the brain.

Paliperidone ER OROS is an atypical antipsychotic that works by blocking dopamine receptors in the brain. Used for Schizophrenia, Schizoaffective disorder.

At a glance

Mechanism of action

By blocking dopamine receptors, Paliperidone ER OROS reduces the symptoms of schizophrenia and schizoaffective disorder. It is a long-acting formulation of paliperidone, which is released slowly over time to maintain therapeutic levels in the bloodstream.

Approved indications

• Schizophrenia
• Schizoaffective disorder

Common side effects

• Weight gain
• Dizziness
• Headache
• Nausea
• Vomiting

Key clinical trials

• A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia (PHASE3)
• A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function (PHASE1)
• A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia (PHASE1)
• A Bioequivalence Study of 15 mg ER OROS Paliperidone (PHASE1)
• A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone (PHASE1)
• A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder (PHASE1)
• As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations (PHASE1)
• A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.